CN102497882A - 包含至少一种肾上腺素能化合物的稳定化组合物 - Google Patents

包含至少一种肾上腺素能化合物的稳定化组合物 Download PDF

Info

Publication number
CN102497882A
CN102497882A CN201080024234XA CN201080024234A CN102497882A CN 102497882 A CN102497882 A CN 102497882A CN 201080024234X A CN201080024234X A CN 201080024234XA CN 201080024234 A CN201080024234 A CN 201080024234A CN 102497882 A CN102497882 A CN 102497882A
Authority
CN
China
Prior art keywords
range
antioxidant
adrenergic compound
pharmaceutical composition
sulfite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201080024234XA
Other languages
English (en)
Chinese (zh)
Inventor
A·J·柏利
K·麦克唐纳
P·波蒂厄斯
S·亨德里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALK Abello AS
Original Assignee
ALK AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALK AG filed Critical ALK AG
Publication of CN102497882A publication Critical patent/CN102497882A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201080024234XA 2009-06-04 2010-06-03 包含至少一种肾上腺素能化合物的稳定化组合物 Pending CN102497882A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18406609P 2009-06-04 2009-06-04
DKPA200900705 2009-06-04
US61/184,066 2009-06-04
DKPA200900705 2009-06-04
PCT/EP2010/057771 WO2010139751A2 (en) 2009-06-04 2010-06-03 Stabilised composition comprising at least one adrenergic compound

Publications (1)

Publication Number Publication Date
CN102497882A true CN102497882A (zh) 2012-06-13

Family

ID=41364279

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201080024234XA Pending CN102497882A (zh) 2009-06-04 2010-06-03 包含至少一种肾上腺素能化合物的稳定化组合物
CN201080024241XA Pending CN102802668A (zh) 2009-06-04 2010-06-03 包含至少一种肾上腺素能化合物的稳定化组合物
CN201610726131.7A Pending CN106109397A (zh) 2009-06-04 2010-06-03 包含至少一种肾上腺素能化合物的稳定化组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201080024241XA Pending CN102802668A (zh) 2009-06-04 2010-06-03 包含至少一种肾上腺素能化合物的稳定化组合物
CN201610726131.7A Pending CN106109397A (zh) 2009-06-04 2010-06-03 包含至少一种肾上腺素能化合物的稳定化组合物

Country Status (15)

Country Link
US (1) US9155694B2 (https=)
EP (2) EP2437781B1 (https=)
JP (2) JP2012528830A (https=)
KR (2) KR20120028344A (https=)
CN (3) CN102497882A (https=)
AU (2) AU2010255747B2 (https=)
BR (2) BRPI1011074A2 (https=)
CA (2) CA2764051A1 (https=)
DK (2) DK2437781T3 (https=)
ES (2) ES2432164T3 (https=)
MX (2) MX2011012732A (https=)
PT (2) PT2437782E (https=)
RU (2) RU2527337C9 (https=)
SI (2) SI2437781T1 (https=)
WO (2) WO2010139752A2 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103520096A (zh) * 2013-10-25 2014-01-22 成都晶博生物科技有限责任公司 一种硫酸特布他林注射液的生产工艺
CN104703587A (zh) * 2012-10-08 2015-06-10 沃克哈特有限公司 肾上腺素及其盐的稳定的可注射药物组合物
CN106061467A (zh) * 2014-02-27 2016-10-26 辛苔蒂加股份有限公司 用于产生去甲肾上腺素的稳定低浓度、可注射溶液的方法
CN107205938A (zh) * 2014-12-18 2017-09-26 温德加普医疗股份有限公司 用于溶解或增溶治疗剂的方法和组合物
CN112138250A (zh) * 2019-06-28 2020-12-29 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
US12239822B2 (en) 2013-03-15 2025-03-04 Windgap Medical, Inc. Portable drug mixing and delivery device and associated methods
US12239823B2 (en) 2013-12-18 2025-03-04 Windgap Medical, Inc. Drug mixing and delivery system and method

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8628805B2 (en) * 2009-06-04 2014-01-14 Alk Ag Stabilized composition comprising at least one adrenergic compound
CN102525893B (zh) * 2012-01-04 2013-11-20 上海禾丰制药有限公司 盐酸去氧肾上腺素注射液及其制剂工艺
CN102525894A (zh) * 2012-01-04 2012-07-04 上海禾丰制药有限公司 盐酸异丙肾上腺素注射液及其制剂工艺
TWI780236B (zh) * 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
EP3052095A4 (en) 2013-10-03 2017-07-05 Imprimis Pharmaceuticals Inc. Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
MX2016008979A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
EP2990031B1 (en) * 2014-08-28 2019-11-13 Sun Pharmaceutical Industries Ltd Parenteral dosage form of norepinephrine
US9119876B1 (en) 2015-03-13 2015-09-01 Par Pharmaceutical, Inc. Epinephrine formulations
US20170189352A1 (en) 2015-03-13 2017-07-06 Par Pharmaceutical, Inc. Epinephrine formulations
US10039710B2 (en) * 2015-09-18 2018-08-07 Insys Development Company, Inc. Epinephrine spray formulations
US11517525B2 (en) * 2015-09-18 2022-12-06 Hikma Pharmaceuticals Usa Inc. Epinephrine spray formulations
EP3503873A4 (en) 2016-08-25 2020-04-15 Harrow IP, LLC EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHOD FOR THE PRODUCTION THEREOF
RU2635759C1 (ru) * 2016-09-13 2017-11-15 Интеллег Сосьете Анониме Фармацевтическая композиция для парентерального введения и способ ее получения
US10835503B2 (en) * 2017-01-13 2020-11-17 Teva Pharmaceuticals Usa, Inc. Pre-filled syringe
WO2018140894A1 (en) 2017-01-30 2018-08-02 Nevakar, Inc Norepinephrine compositions and methods therefor
US20250177328A1 (en) 2017-01-30 2025-06-05 Nevakar Injectables Inc. Norepinephrine compositions and methods therefor
CN111050760A (zh) * 2017-04-17 2020-04-21 希克玛制药美国公司 肾上腺素喷雾制剂
WO2019067505A1 (en) 2017-09-26 2019-04-04 Ys Pharmtech STABILIZATION OF EPINEPHRINE FORMULATIONS
BR112020006950A2 (pt) 2017-10-10 2020-10-06 Merck Patent Gmbh composições farmacêuticas injetáveis estabilizadas de l-epinefrina
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
WO2019183416A1 (en) 2018-03-23 2019-09-26 Nevakar Inc. Epinephrine compositions and containers
WO2019200076A1 (en) 2018-04-11 2019-10-17 QuVa Pharma, Inc. Ready to use liquid reck formulation
US10952962B1 (en) 2018-04-11 2021-03-23 QuVa Pharma, Inc. Ready to use liquid formulation
US10478406B2 (en) 2019-03-18 2019-11-19 HARC Therapeutics AG High-pH solid-state epinephrine formulation
CN114286669A (zh) * 2019-08-08 2022-04-05 太阳医药工业有限公司 去甲肾上腺素的输注剂型
USD1004518S1 (en) 2019-09-09 2023-11-14 Brunswick Corporation Railing for a marine vessel
EP4114336A1 (en) 2020-03-06 2023-01-11 Baxter International Inc. Packaged, sealed container system for stable storage of an oxygen sensitive pharmaceutical formulation
USD984953S1 (en) 2021-05-03 2023-05-02 Brunswick Corporation Safely railing having buoy holder
AU2021203856B2 (en) * 2021-06-10 2023-03-09 Animal Ethics Pty Ltd Topical anaesthetic composition having improved vasoconstrictor stability
US20260027067A1 (en) * 2022-08-27 2026-01-29 Biophore India Pharmaceuticals Pvt. Ltd. Trientine liquid dosage forms

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3149035A (en) * 1961-04-28 1964-09-15 Univ California Stabilization of epinephrine
US3966905A (en) * 1973-05-29 1976-06-29 Barnes-Hind Pharmaceuticals, Inc. Stabilized catechol amine solutions
JPH06298640A (ja) * 1993-04-15 1994-10-25 Nippon Seiyaku Kk 静脈注射剤
US20080269347A1 (en) * 2006-09-28 2008-10-30 Azopharma, Inc. Epinephrine formulations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB425678A (en) 1933-06-15 1935-03-15 Novocol Chemical Mfg Co Inc Improvements relating to anesthetics for hypodermic injection
US2047144A (en) * 1934-03-26 1936-07-07 Lilly Co Eli Stabilized epinephrine-type compound, and process of stabilizing it
US2382546A (en) * 1941-11-03 1945-08-14 Curtis David Anesthetic solutions
US3419035A (en) * 1965-05-25 1968-12-31 Badger Meter Mfg Co Air elimination device for liquid transport system
CA981182A (en) 1972-01-07 1976-01-06 Walter A. Borisenok Stabilization of 1-epinephrine in local anesthetic solutions with a combination of three antioxidants
DD150694A1 (de) 1980-04-16 1981-09-16 Gisela Raether Verfahren zur stabilisierung von pharmazeutischen praeparaten mit oxidationsempfindlichen bestandteilen
US4734438A (en) 1983-04-26 1988-03-29 Macri Frank J Norepinephrine potentiated compositions and method of use
AU5680994A (en) 1992-12-10 1994-07-04 Abbott Laboratories Stabilized catecholamine solutions
US6077545A (en) 1995-10-30 2000-06-20 Matrix Pharmaceuticals, Inc. Process and composition for therapeutic cisplatin (CDDP)
PT941085E (pt) 1996-11-14 2003-08-29 Alza Corp Dispositivo para administracao electricamente assistida de agentes como a lidocaina e a epinefrina
PT948965E (pt) * 1997-07-11 2004-08-31 Toray Industries Composicoes medicinais estaveis contendo um derivado de 4,5-epoximorfinano
JP4393641B2 (ja) 1998-11-26 2010-01-06 久光製薬株式会社 イオントフォレーシス用粘着ゲル組成物及びその装置
EP1326642A2 (en) 2000-09-29 2003-07-16 Board of Trustees operating Michigan State University Catecholamine pharmaceutical compositions and methods
HUE026793T2 (en) 2003-10-01 2016-07-28 Kyowa Hakko Kirin Co Ltd A method for stabilizing an antibody and a stabilized solution-type antibody preparation
UA71839C2 (uk) * 2003-12-30 2007-06-25 Товариство З Обмеженою Відповідальністю "Фарм-Стом" Фармацевтична композиція на основі артикаїну та епінефрину
US20050228336A1 (en) 2004-04-07 2005-10-13 Preston Keusch Electrically assisted lidocaine and epinephrine delivery device having extended shelf-stability
US20060129122A1 (en) 2004-12-06 2006-06-15 Wyrick Ronald E Method and apparatus for delivering epinephrine
WO2007123800A2 (en) 2006-04-03 2007-11-01 Nutramax Laboratories, Inc. Stabilized pentosan polysulfate (pps) formulations and methods of analyzing them
US20070249727A1 (en) * 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US8628805B2 (en) 2009-06-04 2014-01-14 Alk Ag Stabilized composition comprising at least one adrenergic compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3149035A (en) * 1961-04-28 1964-09-15 Univ California Stabilization of epinephrine
US3966905A (en) * 1973-05-29 1976-06-29 Barnes-Hind Pharmaceuticals, Inc. Stabilized catechol amine solutions
JPH06298640A (ja) * 1993-04-15 1994-10-25 Nippon Seiyaku Kk 静脈注射剤
US20080269347A1 (en) * 2006-09-28 2008-10-30 Azopharma, Inc. Epinephrine formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
H.WOLLMANN ET AL.: ""Examination of the efficiency of stabilizing agents in Epinephrine model solutions"", 《PHARMACY》 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104703587A (zh) * 2012-10-08 2015-06-10 沃克哈特有限公司 肾上腺素及其盐的稳定的可注射药物组合物
US12239822B2 (en) 2013-03-15 2025-03-04 Windgap Medical, Inc. Portable drug mixing and delivery device and associated methods
CN103520096A (zh) * 2013-10-25 2014-01-22 成都晶博生物科技有限责任公司 一种硫酸特布他林注射液的生产工艺
CN103520096B (zh) * 2013-10-25 2015-02-25 成都晶博生物科技有限责任公司 一种硫酸特布他林注射液的生产工艺
US12239823B2 (en) 2013-12-18 2025-03-04 Windgap Medical, Inc. Drug mixing and delivery system and method
CN106061467A (zh) * 2014-02-27 2016-10-26 辛苔蒂加股份有限公司 用于产生去甲肾上腺素的稳定低浓度、可注射溶液的方法
CN106061467B (zh) * 2014-02-27 2021-02-05 辛苔蒂加股份有限公司 用于产生去甲肾上腺素的稳定低浓度、可注射溶液的方法
CN107205938A (zh) * 2014-12-18 2017-09-26 温德加普医疗股份有限公司 用于溶解或增溶治疗剂的方法和组合物
US11246842B2 (en) 2014-12-18 2022-02-15 Windgap Medical, Inc. Method and compositions for dissolving or solubilizing therapeutic agents
CN112138250A (zh) * 2019-06-28 2020-12-29 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
CN112138250B (zh) * 2019-06-28 2023-04-14 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器

Also Published As

Publication number Publication date
WO2010139752A3 (en) 2011-04-07
KR20120044309A (ko) 2012-05-07
US20120129944A1 (en) 2012-05-24
AU2010255748B2 (en) 2014-03-13
CN102802668A (zh) 2012-11-28
MX2011012732A (es) 2012-02-28
WO2010139752A2 (en) 2010-12-09
RU2527337C9 (ru) 2014-12-27
US9155694B2 (en) 2015-10-13
ES2432164T3 (es) 2013-12-02
AU2010255748A1 (en) 2011-12-08
BRPI1011074A2 (pt) 2016-04-12
CA2764050C (en) 2017-02-28
JP6087145B2 (ja) 2017-03-01
MX2011012735A (es) 2012-02-28
WO2010139751A3 (en) 2011-04-07
JP2012528831A (ja) 2012-11-15
AU2010255747B2 (en) 2014-03-13
RU2011153403A (ru) 2013-07-20
EP2437782A2 (en) 2012-04-11
JP2012528830A (ja) 2012-11-15
EP2437781B1 (en) 2013-07-24
EP2437782B1 (en) 2013-07-24
BRPI1013019A2 (pt) 2016-03-29
AU2010255747A1 (en) 2012-02-02
DK2437781T3 (da) 2013-10-21
DK2437782T3 (da) 2013-10-28
WO2010139751A2 (en) 2010-12-09
PT2437781E (pt) 2013-10-30
SI2437781T1 (sl) 2013-12-31
SI2437782T1 (sl) 2013-12-31
ES2432241T3 (es) 2013-12-02
CA2764050A1 (en) 2010-12-09
CN106109397A (zh) 2016-11-16
KR20120028344A (ko) 2012-03-22
EP2437781A2 (en) 2012-04-11
RU2527337C2 (ru) 2014-08-27
RU2011153410A (ru) 2013-07-20
RU2527680C2 (ru) 2014-09-10
CA2764051A1 (en) 2010-12-09
PT2437782E (pt) 2013-10-30

Similar Documents

Publication Publication Date Title
US9155694B2 (en) Stabilized composition comprising at least one adrenergic compound
US8628805B2 (en) Stabilized composition comprising at least one adrenergic compound
US20230355551A1 (en) Stabilization of epinephrine formulations
US20190240337A1 (en) Epinephrine formulations for medicinal products
US20110015273A1 (en) Stable pharmaceutical aqueous compositions
US11925608B2 (en) Stabilization of epinephrine formulations
US20220016054A1 (en) Epinephrine parenteral formulations
HK1162976B (en) Stabilised composition comprising at least one adrenergic compound
HK1162976A1 (en) Stabilised composition comprising at least one adrenergic compound
HK1162975B (en) Stabilised composition comprising at least one adrenergic compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160405

Address after: Holm Hess, Denmark

Applicant after: Alk Abello AS

Address before: The Swiss Cortese,

Applicant before: ALK AG

RJ01 Rejection of invention patent application after publication

Application publication date: 20120613

RJ01 Rejection of invention patent application after publication